Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program

摘要 杜克大学和查佩尔山的北卡罗来纳州大学在过去的9年里， 成功的T32成人和儿科临床药理学博士后培训计划，建立在我们的 卓越的研究环境，在儿科药物发现，药物开发， 药代动力学/药效学和药物安全性。这项新的申请旨在确保持续的资金 儿科临床药理学培训计划组成部分的儿科职位。需求 儿科临床药理学家的比例很高，我们在培训临床医生方面有着出色的记录， 科学家，包括儿科医生，以满足这一领域不断增长的劳动力需求。我们有一个很好的， 多元化的申请人群体，合格的申请人比资助职位多得多。该新应用 描述了我们的2年培训计划（3名学员/年），提供强大的领导力，国际- 来自多个学科的公认导师，他们积极参与儿科临床药理学， 广泛的尖端技术和资源，以及独特的协作环境， 机构支持。该计划的国家申请人主要来自儿科医学博士 医学专业培训计划，寻求儿科临床药理学的职业道路，也从 高级临床/转化研究培训中的药学博士。以个性化发展为导向的学员 计划和指导团队，完成儿科临床药理学课程，并参与计划- 具体活动，以获得专业知识，在所有方面的当代儿科临床药理学研究， 为成功的学术，监管或工业职业生涯做好准备，成为未来的领导者和导师 几代儿科临床药理学家。经验丰富的教师导师是根据他们的选择， 研究生产力在至少四个重点领域之一，形成这个培训计划的核心：药物 处置和行动;定量药理学/药物计量学和临床试验设计;个体化 治疗;药物诱导的器官毒性。该儿科培训计划的新内容包括： 更加关注精确给药、使用真实世界数据和药物计量学;扩大试点计划 儿科临床药理学专业和创新领域的培训，包括怀孕和哺乳; 加强专业发展机会;扩大与其他T32计划的合作。一 该培训计划的独特之处在于儿科药物计量学培训的优势。的浓厚兴趣 在儿科临床药理学方面，我们的实习生队伍中， 药理学研究资源在杜克和杜克大学，智力丰富的生物医学科学环境， 三角研究园，以及我们长期以来优秀的研究和培训基础设施联合收割机， 这是一个绝佳的儿科临床药理学培训机会。

ABSTRACT Duke University and the University of North Carolina at Chapel Hill (UNC) have had, for the past 9 years, a successful T32 postdoctoral training program in adult and pediatric clinical pharmacology that builds on our exceptional research environment with world-class programs in pediatric drug discovery, drug development, pharmacokinetics/ pharmacodynamics, and drug safety. This new application aims to secure continued funding of pediatric positions for the pediatric clinical pharmacology training program component. The demand for pediatric clinical pharmacologists is high, and we have an outstanding track record of training clinician- scientists, including pediatricians, to meet the growing workforce needs in this field. We have an excellent and diverse applicant pool with many more qualified applicants than funded positions. This new application describes our 2-year training program (3 trainees/year), which offers strong leadership, internationally- recognized mentors from multiple disciplines who are actively involved in pediatric clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program is derived primarily from MDs in pediatric medical specialty training programs seeking a career path in pediatric clinical pharmacology, and also from PharmDs in advanced clinical/translational research training. Trainees, guided by individualized development plans and mentoring teams, complete pediatric clinical pharmacology coursework and engage in program- specific activities to gain expertise in all aspects of contemporary pediatric clinical pharmacology research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to future generations of pediatric clinical pharmacologists. Experienced faculty mentors are chosen based on their research productivity in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design; Individualized Therapy; Drug-induced Organ Toxicity. Novel components of this pediatric training program include an increased focus on precision dosing, use of real-world data, and pharmacometrics; pilot programs to expand pediatric clinical pharmacology training in specialty and innovative areas including pregnancy and lactation; enhanced professional development opportunities; and expansion of collaborations with other T32 programs. A unique feature of this training program is the strength in pediatric pharmacometrics training. The keen interest in pediatric clinical pharmacology within our trainee pool, the unparalleled investment in pediatric clinical pharmacology research resources at Duke and UNC, the intellectually-rich biomedical science environment of Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in pediatric clinical pharmacology.